Portfolio / Brunel Laboratoria

Deal Summary

A private equity consortium comprising Umoya Capital Partners and RMB Corvest have, alongside management and Calibre Capital, invested in Brunel Laboratoria (Pty) Ltd.  The deal is the first asset acquired into the Umoya Pharma portfolio, while extending RMB Corvest’s portfolio in the fast-growing healthcare sector.

The company

Brunel is a pharmaceutical brand owner and distributor, with a portfolio of products spanning the scheduled and complementary medicine, health supplement and dispensary consumable segments.  The business has been operating in South Africa for over 40 years and has a well-established consumer base. The business’ brands include Mist Alba, Famucaps, B.Co, Multivit, Hot Toddy and Elev8 among a range of others.

"We look forward to working with our new partners, leveraging off their expertise while continuing with the solid platform laid out by the existing management team. We are confident that this new partnership will drive growth opportunities and hence add significant value to our business and our long-term market strategy." Paul Jonker, Brunel CEO